Archive - January 2019
KemPharm Announces FDA Approval of sNDA for Two Additional Strengths of Apadaz (4.08 mg benzhydrocodone/325 mg APAP and 8.16 mg benzhydrocodone/325 mg APAP)
Nabriva Therapeutics Announces Acceptance of the New Drug Application for Intravenous Contepo to Treat Complicated Urinary Tract Infections by FDA
Merck’s backing of NGM Bio yields NASH drug deal
Lilly adds to pharma M&A run with $8bn Loxo buy-out
BMS and Celgene deal sparks debate on pharma profit motive, more M&A
Sanofi and Regeneron re-jig immuno-oncology deal
NHS Long Term Plan to save up to 500,000 lives
Janssen files Stelara in Europe for ulcerative colitis